2017
Authors: Nascimento OJM, Frontera JA, Amitrano DA, Bispo de Filippis AM, Da Silva IRF; RIO-GBS-ZIKV Research Group
Published in: Neurology 2017;88(24):2330-2332
2017
Authors: Palma P, Chan M, Goodall R, Judd A, Gibb D, Babiker A, Rojo P.
Published: 35th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), May 23rd-27th May, 2017, Madrid
Background A major obstacle to curing HIV infection is persistence of virus as integrated proviral DNA in long-lived cells even after many years on ART.
2017
Authors: Palma P, Zangari P, Cotugno N, Rocca S, Nastouli E, McCoy LE, Ferns RB, Pahwa S, Rossi P
Published: 24th Conference on Retroviruses and Opportunistic Infections, February 13th – 16th, 2017, Seattle. P_1975.
Background It is still unknown whether the paucity of HIV-specific immune responses in early-treated (treated within 6 months of age; ET) HIV-infected children may represent a limitation or an advantage in the perspective of immune therapeutic studies.
2017
Authors: Colbers A, Schalkwijk S, Konopnicki D, Gingelmaier A, Lambert J, van der Ende I, Moltó J, Burger D.
Published: 24th Conference on Retroviruses and Opportunistic Infections, February 13th – 16th, 2017 – Seattle. Abstract number 754.
2017
Authors: Bernays S, Paparini S, Seeley J, Rhodes T.
Published in: Med Anthropol. 2017;36(5):485-499.
Abstract: Global health priorities are being set to address questions on adherence to HIV antiretroviral therapy in adolescence. Few studies have explored young people’s perspectives on the complex host of social and relational challenges they face in dealing with their treatment in secret and their condition in silence.
2017
Authors: Schomaker M, Leroy V, Wolfs T, et al. On behalf of theIeDEA West and Southern Africa regional collaborations and COHERE in EuroCoord.
Published in: Int J Epidemiol. 2017;46(2):453-465.
Background: There is limited knowledge about the optimal timing of antiretroviral treatment initiation in older children and adolescents.
Methods: A total of 20 576 antiretroviral treatment (ART)-naïve patients,
2017
Authors: Volynets G, Skyortsowa TA, Ptapov AS, et al.
Published in: EASL, 19th – 23rd April 2017, Amsterdam
2017
Authors: Thorne C, Turkova A, Indolfi G, Venturini E, Giaquinto C
Published in: AIDS. 2017;31(1):127-135.
Objective To characterize children, adolescents and young adults infected with HIV/hepatitis C virus (HCV) vertically or before age of 18 years and living in Europe regarding mode of acquisition, HCV genotype, clinical status and treatment.
Design Retrospective,
2017
Authors: Majekodunmi AO, Thorne C, Malyuta R, et al.
Published in: Pediatr Infect Dis J. 2017;36(5):e123-e129
Objective To compare CD4 T cell recovery in HIV/HCV coinfected children with recovery in HIV monoinfected children.
2017
Authors: Indolfi G, Thorne C, El-Sayed MH, Giaquinto C, Gonzalez-Peralta RP.
Published in: J Pediatr Gastroenterol Nutr. 2017;64(6):851-854
Abstract The development of oral hepatitis C virus (HCV) direct-acting antivirals (DAAs) has revolutionized the therapeutic field. Nowadays, multiple safe and highly effective antiviral regimens are commercially available to treat adults with hepatitis C infection.
2017
Authors:
Published in: Pediatr Infect Dis J.
2016
Authors: Colbers A, Best B, Schalkwijk S, et al. PANNA Network and the IMPAACT 1026 Study Team.
Published in: Clin Pharmacokinet. 2016;55(3):381-96
Abstract Pregnant women are usually excluded from clinical trials. Physiologically based pharmacokinetic (PBPK) modelling may provide a method to predict pharmacokinetics in pregnant women, without the need to perform extensive in vivo clinical trials.
2016
Authors: Ramos-Martin R , Johnson A, Livermore J, et al.
Published in: J Antimicrob Ther 2016;71(4):992-1002
2016
Authors: Bailey H, Malyuta R, Townsend C, Cortina Borja M, Thorne C for the Ukraine European Collaborative Study in EuroCoord.
Published in: Reprod Health. 2016;22(3):13-27.
Background Perinatal depression among HIV-positive women has negative implications for HIV-related and other maternal and infant outcomes. The aim of this study was to investigate the burden and correlates of perinatal depression among HIV-positive women in Ukraine,
2016
Authors: Safadi MA
Published in: Amer J Perinatol.2016; 33(11): 1029-1031
Abstract Zika virus (ZIKV) is an emerging arthropod-borne, enveloped RNA virus of the Flaviviridae family, which belongs to the genus Flavivirus, related to dengue, yellow fever, Japanese encephalitis, and West Nile viruses. Two major lineages, African and Asian, have been identified through phylogenetic analyses.
2016
Authors: Davidson T., Vickers I., Christie CD
Published in: West Indian Med J 2016;65(3);442-449
Background Dengue fever is hyper-endemic in Jamaica with exponential rates of infection in successive outbreaks. The absence of local data and the potential for massive outbreaks in a country where a third of the population are children formed the basis for this study.
2016
Authors: Christie CD, Melbourne-Chambers R, Ennevor J, et al.
Published in: West Indian Med J 2016;65(3);431-437
Background Chikungunya virus entered the Caribbean for the first time in 2013 and Jamaica experienced its maiden epidemic with Chikungunya Fever in 2014. We aimed to describe the public health effects and describe the clinical features in children and adolescents in Jamaica.
2016
Authors: Webster-Kerr K, Christie CDC, Grant A, et al.
Published in: West Indian Med J. 2016;65(1):243-249
Background Jamaica, along with the Americas, experienced major epidemics of arboviral diseases transmitted by the Aedes aegypti mosquito in recent years. These include dengue fever in 2012, chikungunya fever in 2014 and Zika virus infection (ZIKV) in 2016. We present the emergence of the ZIKV epidemic in Jamaica and outline the national response.
2016
Authors: Oliveira DB, Almeida FJ, Durigon EL, et al.
Published in: N Engl J Med. 2016. 22;375(12):1202-4
The presence of Zika virus (ZIKV) infection has been associated with microcephaly in multiple studies, although little is known about ZIKV shedding in congenitally infected infants. We report a case of a newborn who had continued viremia with ZIKV for at least 67 days after birth.
2016
Authors: Christie CD, Giaquinto C
Published in: West Indian Med J.2016;65(1):239-242
Abstract Zika virus epidemic now involves 72 countries, worldwide. Transmission is multimodal through mosquito bites and blood and body fluids. Zika virus causes Guillain Barre Syndrome syndrome and pregnancy complications including perinatal microcephaly. Diagnosis is complicated by subclinical infection in 80%,
2016
Authors: Bocanegra C, Sulleiro E, Soriano-Arandes A, et al.
Published in: Clin Microbiol Infect. 2016;22(7):648-50
This case series of two pregnant women infected with the Zika virus in Barcelona, Spain and provides an algorithm for diagnosing pregnant women with suspected ZIKV infection in non-endemic areas.
2016
Authors: Capua I
Published in: Nature. 2016;16;534(7607):326
This correspondence urges Brazil to speed up reforms to current biosecurity legislation, enabling sharing of vital Zika virus samples and information.
2016
Authors: Kednicky J, Beau De Rochars VM, El Badry M, et al.
Published in: PLoS Negl Trop Dis. 2016;10(4):e0004687
Background Zika virus (ZIKV), first isolated in Uganda in 1947, is currently spreading rapidly through South America and the Caribbean. In Brazil, infection has been linked with microcephaly and other serious complications,
2016
Authors: Solomon T, Baylis M, Brown D.
Published in: Lancet Infect Dis. 2016;16(4):402-404
This article comments on the origins and consequences of recent Zika virus outbreaks, highlighting the urgent need to address several key gaps in knowledge regarding this virus.
2016
Author: Bispo A
Published in: Bull World Health Organ. 2016;94:165–166
In this interview, Anna Bispo describes the history of Zika virus in Brazil, including its potential links to an increase in microcephaly cases, and describes groundbreaking work in Zika virus diagnostics and virology at the Oswaldo Cruz Foundation in Rio de Janeiro, Brazil.
2016
Authors: Turkova A, Chappell E, Chalermpantmetagul S, et al.
Published in: Int J Tuberc Lung Dis 2016;20(11):1448-1456.
Setting Centres participating in the Paediatric European Network for Treatment of AIDS (PENTA), including Thailand and Brazil.
Objective To describe the incidence, presentation, treatment and treatment outcomes of tuberculosis (TB) in human immunodeficiency virus (HIV) infected children.
2016
Authors: European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.
Published in: Antivir Ther. 2016; 21(4): 353-8
Background Surveillance for mid- and long-term antiretroviral therapy (ART) toxicity in children is important for informing treatment guidelines. We assessed the safety of darunavir (DRV) and atazanavir (ATV), commonly used as second-line protease inhibitors following lopinavir/ritonavir,
2016
Authors: Judd A, Sohn A, Collins J.
Published in: Curr Opin HIV AIDS 2016;11(5):477-486.
Purpose of review There is an increasing number of deaths among adult survivors of perinatal HIV. Multiple and complex factors drive this mortality, including problems with retention in care and adherence during adolescence,
2016
Authors: Ngo-Giang-Huong N, Wittkop L, Judd A, et al. For EuroCoord-CHAIN-EPPICC joint project study group.
Published in: BMC Infect Dis. 2016;16(1):654.
Background Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
2016
2016
Authors: Schalkwijk S, ter Heine R, Colbers A, Huitema A, Denti P, Dooley K, Capparelli E, Best B, Cressey T, Greupink R, Russel F, Mirochnick M, Burger D.
Published: 17th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, June 8th-10th 2016, Washington DC. P_26
2016
Authors: Colbers A, Schalkwijk S, Konopnicki D, Hawkins D, Hidalgo Tenorio C, Moltò J, Taylor G, Weizsacker K, van der Ende M, Burger D
Published: Oral presentation at 17th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, June 8th-10th 2016, Washington DC
2016
Authors: Schalkwijk S, Best B, Colbers A, SteK A, Wang J, Hawkins D, Mirochnick M, Burger D; for the The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1026s Protocol Team, and the Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-infected Pregnant Women (PANNA) Study Network
Published: 23rd Conference on Retroviruses and Opportunistic Infections, February 22nd-25th 2016, Boston
2016
Authors: Blonk MI, Colbers AP, HidalgoTenorio C, et al.
Published in: Front Pharmacol. 2016 Aug 4;7:239.
Background: The study goal was to describe etravirine pharmacokinetics during pregnancy and postpartum in HIV-infected women.
Methods: IMPAACT P1026s and PANNA are on-going, non-randomized, open-label, parallel-group, multi-center phase-IV prospective studies in HIV-infected pregnant women.
2016
Authors: Schalkwijk S, Feiterna-Sperling C, Weizsacker K, et al.
Published in: AIDS. 2016; 30(12):1999-2001.
No Abstract available
2016
Author: Butler K, Inshaw J, Ford D, et al.
Published in: Health Technol Assess. 2016;20(49):1-108.
Background For human immunodeficiency virus (HIV)-infected adolescents facing lifelong antiretroviral therapy (ART), short-cycle therapy (SCT) with long-acting agents offers the potential for drug-free weekends, less toxicity, better adherence and cost savings.
Objectives To determine whether or not efavirenz (EFV)-based ART in short cycles of 5 days on and 2 days off is as efficacious (in maintaining virological suppression) as continuous EFV-based ART (continuous therapy;
2016
Author: The BREATHER (PENTA 16) Trial Group
Published in: Lancet HIV. 2016;3(9):e421-430
Background For HIV-1-infected young people facing lifelong antiretroviral therapy (ART), short cycle therapy with long-acting drugs offers potential for drug-free weekends, less toxicity, and better quality-of-life. We aimed to compare short cycle therapy (5 days on, 2 days off ART) versus continuous therapy (continuous ART).
2016
Authors: Schalkwijk S, Colbers A, Konopnicki D, et al. For PANNA network
Published in: AIDS. 2016;30(8):1239-44.
Objective To describe the pharmacokinetics of abacavir 600 mg once daily (q.d.) in HIV-1-positive women during pregnancy and postpartum.
Design A nonrandomized, open-label, multicentre, phase-IV study.
Methods HIV-positive pregnant women receiving abacavir 600 mg q.d.
2016
Authors: Aebi-Popp K, Bailey H, Malyuta R, Volokha A, Thorne C. Ukraine European Collaborative Study in EuroCoord.
Published in: BMC Pregnancy Childbirth. 2016;27;16:94
Background Over 3500 HIV-positive women give birth annually in Ukraine, a setting with high prevalence of sexually transmitted infections. Herpes simplex virus Type 2 (HSV-2) co-infection may increase HIV mother-to-child transmission (MTCT) risk.
2016
Authors: Ananworanich J, Melvin D, Ramos Amador JT, et al; on behalf of the PENTA 11 study group.
Published in: AIDS. 2016;30(7):1075-81.
Objective Understanding the effects of antiretroviral treatment (ART) interruption on neurocognition and quality of life (QoL) are important for managing unplanned interruptions and planned interruptions in HIV cure research.
Design Children previously randomized to continuous (continuous ART,
2016
Authors: Schalkwijk S, Colbers A, Konopnicki D, Greupink R, Russel FG, Burger D; PANNA network.
Published in: AIDS. 2016;30(5):807-8.
Abstract not available
2016
Authors: Writing group for the Kids to Adults Working Group and Data Management and Harmonisation Group in EuroCoord.
Published in: Euro Surveill.2016;21(10): 30162
Abstract Accurate ascertainment of the number of children living with human immunodeficiency virus (HIV) is important to plan paediatric and adolescent health services. In Europe, the first generation of perinatally HIV-infected survivors are transferring to adult care and their health needs are unknown.
2016
Author: Warris A; European Paediatric Mycology Network (EPMyN)*.
Published in: Curr Fungal Infect Rep. 2016;10:7-9.
Abstract: The European Paediatric Mycology Network (EPMyN) was launched in 2014 to create a European platform for research and education in the field of paediatric mycology. The EPMyN aims to address the lack of paediatric specific evidence and knowledge needed to (1) improve the management and outcome of invasive fungal infections in children and neonates and to (2) enhance and develop paediatric anti-fungal stewardship programmes.
2016
Authors: S. Bernays, S. Paparini, D. Gibb & J. Seeley
Published in: Vulnerable Child Youth Stud. 2016;11(1):60-68
Abstract Despite mounting evidence recommending disclosure of human immunodeficiency virus (HIV) status to young people with perinatally acquired HIV as a central motivating factor for adherence to antiretroviral therapy, many young people continue to experience disclosure as a partial event,
2015
Authors: Moltò J, Valle M, Colbers A, Clotet V, Burger D.
Published: 16th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26th – 28th 2015, Westin Alexandria
2015
Authors: Harrison L, Melvin A, Fiscus S, et al. For PENPACT-1 (PENTA 9PACTG 390) Study Team.
Published in: JAIDS 2015;70(1):42-53
Background The PENPACT-1 trial compared virologic thresholds to determine when to switch to second-line antiretroviral therapy (ART). Using PENPACT-1 data, we aimed to describe HIV-1 drug resistance accumulation on first-line ART by virologic threshold.
Methods PENPACT-1 had a 2 × 2 factorial design,
2015
Authors: Bernays S, Seeley J, Paparini S, Rhodes T
Published: BSA Medical Sociology Conference, York, 9-11 September 2015 (Paper ID No: W0012148)
2015
Authors: Blonk MI, Colbers AP, Hidalgo-Tenorio C, et al. Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women PANNA Network; PANNA Network.
Published in: Clin Infect Dis. 2015; 61(5):809-816.
BackgroundThe use of raltegravir in human immunodeficiency virus (HIV)–infected pregnant women is important in the prevention of mother-to-child HIV transmission,
2015
Authors: Colbers A, Clotet V, Burger D.
Published: 16th edition of the International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26th – 28th 2015, Westin Alexandria
2015
Authors: Best B, Colbers A, Wang J, Taylor G, Stek A, van Kasteren M, Mirochnick M, Burger D.
Published: 24th Conference on Retroviruses and Opportunistic Infections, March 23rd-26th 2015, Seattle. P_892